Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 20:15:418-420.
doi: 10.18632/oncotarget.28598.

HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity

Marcus Schmidt, Hans-Anton Lehr, Katrin Almstedt
Editorial

HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity

Marcus Schmidt et al. Oncotarget. .
No abstract available

Keywords: HER2; HER2-low; breast cancer; predictive; prognostic.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

M. Schmidt reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, Marcus Schmidt has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1 issued. H-A. Lehr declares that he has no conflict of interest. K. Almstedt received speaker honoraria from Roche Pharma AG, Pfizer Pharma GmbH and AstraZeneca.

References

    1. Ross JS, et al.. Oncologist. 1998; 3:237–52. - PubMed
    1. Balduzzi S, et al.. Cochrane Database Syst Rev. 2014; 2014:CD006242. 10.1002/14651858.CD006242.pub2. - DOI - PMC - PubMed
    1. Moja L, et al.. Cochrane Database Syst Rev. 2012; 2012:CD006243. 10.1002/14651858.CD006243.pub2. - DOI - PMC - PubMed
    1. Wolff AC, et al.. J Clin Oncol. 2018; 36:2105–22. 10.1200/JCO.2018.77.8738. - DOI - PubMed
    1. Fehrenbacher L, et al.. J Clin Oncol. 2020; 38:444–53. 10.1200/JCO.19.01455. - DOI - PMC - PubMed

Publication types